Last updated: 5 September 2024 at 4:03pm EST

Marion McCourt Net Worth




The estimated Net Worth of Marion Mc Court is at least $29.8 Milion dollars as of 3 September 2024. Ms. Court owns over 1,000 units of Regeneron Pharmaceuticals stock worth over $15,901,540 and over the last 8 years she sold REGN stock worth over $3,642,355. In addition, she makes $10,224,700 as Senior Vice President - Commercial at Regeneron Pharmaceuticals.

Ms. McCourt REGN stock SEC Form 4 insiders trading

Marion has made over 46 trades of the Regeneron Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 1,000 units of REGN stock worth $381,400 on 3 September 2024.

The largest trade she's ever made was exercising 2,000 units of Regeneron Pharmaceuticals stock on 20 August 2020 worth over $685,860. On average, Marion trades about 596 units every 22 days since 2017. As of 3 September 2024 she still owns at least 13,931 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Ms. Court stock trades at the bottom of the page.





Marion McCourt biography

Marion McCourt serves as Senior Vice President - Commercial of the Company. From April 2017 until joining the Company, Ms. McCourt served as the Principal Operating Officer and the Chief Operating Officer and President of Axovant Sciences, Inc. Ms. McCourt previously served as chief operating officer of Medivation, Inc. from February 2016 until its acquisition by Pfizer Inc. in September 2016. Previously, Ms. McCourt worked at Amgen Inc., where she most recently served as a Vice President in U.S. Commercial Operations from February 2014 to January 2016. From May 2013 to January 2014, Ms. McCourt served as Vice President and General Manager at Amgen where she was responsible for the bone health and primary care business unit. From 2012 to 2013, she was Chief Operating Officer for AstraZeneca U.S., a division of AstraZeneca plc. Her responsibilities included oversight and leadership of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, and corporate affairs. During her 12-year tenure at AstraZeneca, Ms. McCourt was President and Chief Executive Officer of AstraZeneca Canada Inc. from 2011 to 2012 and also held various other roles at AstraZeneca Pharmaceuticals LP, a subsidiary of AstraZeneca plc. Ms. McCourt received her B.S. in Biology from Lafayette College.

What is the salary of Marion McCourt?

As the Senior Vice President - Commercial of Regeneron Pharmaceuticals, the total compensation of Marion McCourt at Regeneron Pharmaceuticals is $10,224,700. There are 3 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.



How old is Marion McCourt?

Marion McCourt is 60, she's been the Senior Vice President - Commercial of Regeneron Pharmaceuticals since 2018. There are 14 older and 7 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis oraz Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.



What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.



Complete history of Ms. Court stock trades at CytomX Therapeutics Inc, Regeneron Pharmaceuticals oraz Scynexis Inc

Osoba
Trans.
Transakcja
Łączna cena
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $381,400
3 Sep 2024
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $423,487
1 Aug 2024
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $423,487
1 Jul 2024
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $423,859
3 Jun 2024
Marion Mc Court
EVP Commercial
Sprzedaż $222,353
1 May 2024
Marion Mc Court
EVP Commercial
Sprzedaż $241,183
1 Apr 2024
Marion Mc Court
EVP Commercial
Sprzedaż $346,365
1 Mar 2024
Marion Mc Court
EVP Commercial
Sprzedaż $934,710
5 Feb 2024
Marion Mc Court
EVP Commercial
Sprzedaż $258,152
1 Feb 2024
Marion Mc Court
EVP Commercial
Sprzedaż $239,451
2 Jan 2024
Marion Mc Court
EVP Commercial
Sprzedaż $226,379
8 Dec 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $381,400
1 Nov 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $386,613
2 Oct 2023
Marion Mc Court
EVP Commercial
Sprzedaż $208,638
1 Sep 2023
Marion Mc Court
EVP Commercial
Sprzedaż $186,165
1 Aug 2023
Marion Mc Court
EVP Commercial
Sprzedaż $177,523
3 Jul 2023
Marion Mc Court
EVP Commercial
Sprzedaż $184,000
1 Jun 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
3 Apr 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
1 Mar 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $372,460
7 Feb 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
1 Feb 2023
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
3 Jan 2023
Marion Mc Court
EVP Commercial
Sprzedaż $192,765
9 Dec 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
1 Dec 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $372,460
4 Nov 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $409,706
1 Nov 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $394,944
3 Oct 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $377,223
1 Sep 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $377,223
1 Aug 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $377,223
1 Jul 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $377,223
1 Jun 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $377,223
2 May 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Apr 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Mar 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Feb 2022
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
3 Jan 2022
Marion Mc Court
EVP Commercial
Sprzedaż $224,673
11 Dec 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Dec 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Nov 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Oct 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Sep 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
2 Aug 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
1 Jul 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
7 Jun 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $342,930
7 May 2021
Marion Mc Court
EVP Commercial
Opcja Ćwiczenie $685,860
20 Aug 2020


Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: